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STUDY QUESTION: Is the length of FMR1 repeat alleles within the normal range associated with the risk of early menopause?
SUMMARY ANSWER: The length of repeat alleles within the normal range does not substantially affect risk of early menopause.
WHAT IS KNOWN ALREADY: There is a strong, well-established relationship between length of premutation FMR1 alleles and age at
menopause, suggesting that this relationship could continue into the normal range. Within the normal range, there is conﬂicting evidence; dif-
ferences in ovarian reserve have been identiﬁed with FMR1 repeat allele length, but a recent population-based study did not ﬁnd any associ-
ation with age at menopause as a quantitative trait.
STUDY DESIGN, SIZE, DURATION: We analysed cross-sectional baseline survey data collected at recruitment from 2004 to 2010
from a population-based, prospective epidemiological cohort study of >110 000 women to investigate whether repeat allele length was asso-
ciated with early menopause.
PARTICIPANTS/MATERIALS, SETTING, METHOD: We included 4333 women from the Breakthrough Generations Study (BGS),
of whom 2118 were early menopause cases (menopause under 46 years) and 2215 were controls. We analysed the relationship between
length of FMR1 alleles and early menopause using logistic regression with allele length as continuous and categorical variables. We also
conducted analyses with the outcome age at menopause as a quantitative trait as well as appropriate sensitivity and exploratory analyses.
MAIN RESULTS AND THE ROLE OF CHANCE: There was no association of the shorter or longer FMR1 allele or their combined
genotype with the clinically relevant end point of early menopause in our main analysis. Likewise, there were no associations with age at
menopause as a quantitative trait in our secondary analysis.
LIMITATIONS, REASONS FOR CAUTION:Women with homozygous alleles in the normal range may have undetected FMR1 premu-
tation alleles, although there was no evidence to suggest this. We estimate minor dilution of risk of early menopause from the likely inclusion
of some women with menopause at over 45 years in the early menopause cases due to age-rounding bias in self-reports.
WIDER IMPLICATIONS OF THE FINDINGS: There is no robust evidence in this large study that variation within the normal range of
FMR1 repeat alleles inﬂuences timing of menopause in the general population, which contradicts ﬁndings from some earlier, mainly smaller
studies. The FMR1 CGG repeat polymorphism in the normal range is unlikely to contribute to genetic susceptibility to early menopause.
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Introduction
Previous studies have suggested that normal variation in number of
CGG repeats in FMR1 could inﬂuence age at menopause. The 5′
untranslated region of the FMR1 gene contains a CGG repeat that var-
ies in length, causing Fragile X syndrome at over 200 repeats, with
methylation and silencing of the FMR1 gene and lack of FMRP expres-
sion. While ovarian function remains normal in women with full muta-
tion range repeat alleles, primary ovarian insufﬁciency (POI) occurs in
20% of women with alleles in the premutation range of FMR1 (55–200
repeats) (Allen et al., 2014).
In the premutation range, FMRP is expressed although there are ele-
vated levels of FMR1 mRNA, which have been found to sequester
mRNA binding proteins. Although the mechanism of causation for POI
remains unknown, premutation range alleles impair follicle develop-
ment and induce apoptosis in mouse models (Lu et al., 2012). Also,
there is a non-linear relationship between length of premutation alleles
that have a dominant genetic effect and age at menopause, with earli-
est menopause at around 80 copies and later menopause at lower and
higher copy numbers (Sullivan et al., 2005; Ennis et al., 2006; Mailick
et al., 2014). It has been hypothesised that this relationship with age at
menopause may continue to be observed in the range for normal
length alleles (<55 repeats).
In white Europeans, the lowest observed allele length is six CGGs,
and there are peaks in the distribution at 20, 23 and 30 CGGs, with
30 repeats being the most common (Murray et al., 1996). Previous
studies have deﬁned subgroups based on allele length and have
reported differences in ovarian reserve between these (Gleicher
et al., 2009, 2010, 2012a,b). In some studies, a greater proportion of
longer normal length FMR1 alleles have been found in women with
POI or diminished ovarian reserve (Bretherick et al., 2005; Bodega
et al., 2006; Pastore et al., 2012). However, many of these studies
were composed of fewer than 500 women. Other analyses, including
two large studies in over 3000 women by Voorhuis et al., have not
found an association between longer length normal FMR1 alleles and
POI (Bennett et al., 2010; Voorhuis et al., 2014) and no relationship
between normal length FMR1 alleles and age at menopause
(Voorhuis et al., 2013). We tested the role of normal-sized FMR1
CGG repeat alleles in menopause timing in a cohort of over 2000
early menopause cases, plus over 2000 controls, drawn from a
population-based study of over 110 000 women from the
Breakthrough Generations Study (BGS).
Materials andMethods
Participants included
In this analysis, we included 4333 women from the BGS recruited
from 2004 to 2010. The BGS is a prospective population cohort
study started in 2003 to investigate the environmental, behavioural,
hormonal and genetic causes of breast cancer (Swerdlow et al., 2011)
(http://www.breakthroughgenerations.org.uk/). The BGS cohort includes
over 110 000 women aged 16 and older at entry, recruited from the general
UK population through connections to the charity Breakthrough Breast
Cancer or who volunteered as a result of publicity, and female friends and
family members of these participants. The study received appropriate ethical
approval from the South East MREC, and informed consent was received
from the participants (Swerdlow et al., 2011). Detailed menstrual histories
and blood samples were collected. All women with early menopause were
eligible for inclusion in our analyses. Breast cancer cases were excluded from
our analyses. Of the women included, 99.5% were of white ethnicity
(Table I).
Deﬁnition of age at natural menopause
Natural menopause was deﬁned as cessation of menstruation for at least
6 months without known cause based on questionnaire data (‘Have
your periods now stopped completely? (That is, have you now gone at
least 6 months without having a period and you are not pregnant or on
the contraceptive pill)’). We excluded women if periods stopped
because of pregnancy, breastfeeding, surgery, hormonal contraceptive
use or other types of medical treatment or if there was a medical condi-
tion or illness that could have caused amenorrhoea (e.g. polycystic ovary
syndrome).
Early menopause cases and controls
A nested case–control design was used for reasons of cost-effectiveness.
Early menopause cases had natural menopause at age 45 years or younger,
whereas controls were women known to have had menopause (natural or
surgical) at 46 years or older or, to allow sufﬁcient suitable controls to be
identiﬁed, women who were aged 46 years or older and were premeno-
pausal. Where possible, controls were matched to cases on date of birth
(within 12 months), ethnicity, year of questionnaire completion and source
of recruitment. Where this was not possible, matching criteria were
relaxed in the following order until a match was found: source of recruit-
ment, year of completion and date of birth. Early menopause cases aged
45 years or younger were matched to a control aged 46 years, since all
postmenopausal women aged 45 years or younger were early menopause
cases. In order to exclude subjects who were genetically related to each
other, we identiﬁed mother–daughter and sister–sister pairs among the
selected subjects. We excluded the oldest subject when both of the indivi-
duals were cases or controls. When one was a case and the other a con-
trol, the control was replaced. Following genotyping and data cleaning,
4333 women remained in our analysis, of whom 2215 were early meno-
pause cases (including 250 women with menopause under 40 years) and
2118 were controls.
Evaluation of FMR1 repeat length
For each subject, Asuragen Amplidex kits (http://www.asuragen.com)
containing FMR1 CGG repeat region–speciﬁc primers were used to PCR
amplify the FMR1 repeat region from 20 ng of genomic DNA that had
been extracted from peripheral blood mononuclear cells. All PCRs were
performed in 3 μl of reaction volumes in 384-well microtiter plates, using
conditions recommended by the kit manufacturers. Products were size
separated by capillary electrophoresis on an ABI 3730 automated
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Table I Summary statistics for individuals included in the analysis (all variables measured at recruitment unless otherwise
speciﬁed).
Early menopause
cases
Controls Post-menopausal
women included
in quantitative
trait analysis
Age (years) n = 2118 n = 2215 n = 3805
Mean (range) 58.5 (22,88) 59.4 (45,89) 60.3 (22,89)
Median (lower quartile, upper quartile) 58 (52,64) 59 (53,65) 60 (55,66)
Year of entry n = 2118 n = 2215 n = 3805
Mean (range) 2006 (2004, 2009) 2006 (2004, 2010) 2006 (2004, 2010)
Median (lower quartile, upper quartile) 2006 (2005, 2007) 2006 (2005, 2007) 2006 (2005, 2007)
Age at menopause n = 2118 n = 1687 n = 3805
Mean (range) 42.5 (19,45) 52.1 (46,62) 46.7 (19,62)
Median (lower quartile, upper quartile) 43 (41,45) 52 (50,54) 45 (43,52)
BMI at age 20 n = 1684 n = 1801 n = 3053
Mean (range) 21.3 (12,56.5) 21.4 (12.4,38.3) 21.3 (12,56.5)
Median (lower quartile, upper quartile) 21 (19.6,22.6) 21.1 (19.8,22.7) 21 (19.7,22.6)
BMI (kg/m2) n = 2041 n = 2148 n = 3676
Mean (range) 25.8 (5.1,63.2) 25.6 (14.9,54.4) 25.7 (5.1,63.2)
Median (lower quartile, upper quartile) 24.9 (22.7,28) 24.9 (22.6,27.6) 24.9 (22.7,27.8)
Height (m) n = 2082 n = 2192 n = 3750
Mean (range) 1.63 (1.27,2.06) 1.63 (1.37,1.83) 1.63 (1.27,2.06)
Median (lower quartile, upper quartile) 1.63 (1.58,1.68) 1.63 (160,1.68) 1.63 (1.58,1.68)
Number of births (live and still) at ≥26 weeks gestation
(includes never pregnant)
n = 2111 n = 2210 n = 3795
Mean (range) 1.9 (0,10) 2.1 (0,8) 2.0 (0,10)
Median (lower quartile, upper quartile) 2 (1,3) 2 (2,3) 2 (1,3)
n % n % n %
Ethnicity
White ethnicity 2107 99.5 2204 99.5 3787 99.5
Non-white 11 0.5 11 0.5 18 0.5
Smoking status
Never smoker 1242 58.6 1401 63.3 2299 60.4
Former smoker 683 32.3 714 32.2 1146 32.8
Current smoker 187 8.8 99 4.5 252 6.7
Smoking status not known 6 0.3 1 0.1 7 0.2
Hormone replacement therapy use
Never 1036 48.9 1526 68.9 2077 54.6
Former 752 35.5 539 24.3 1268 33.3
Current 323 15.3 147 6.6 450 11.8
Not known 7 0.3 3 0.1 10 0.3
Oral contraceptive use
Never 526 24.8 584 26.4 1065 28.0
Former 1569 74.1 1591 71.8 2711 71.3
Current 11 0.5 35 1.6 12 0.3
Not known 12 0.6 5 0.2 17 0.4
Total 2118 2215 3805
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sequencer (Applied Biosystems, Warrington, UK), using a ROX 1000 size
standard (Asuragen, Austin, TX, USA) for estimation of product sizes.
CGG repeat numbers were determined by comparison with a control indi-
vidual of 52 CGG repeats. We included duplicates of ~10% of the samples
on independent plates. The concordance between duplicate samples was
98.5%, excluding differences of ±1 CGG repeat. Controls included 12 no-
template controls, 3 samples from females of known expansion size (lar-
gest CGG = 55, 117 and 145) and a lane containing the multiple size tar-
gets supplied by Asuragen (CGG = 20, 29, 31, 53, 117 and 196) per 384
plate.
Statistical analyses
We analysed the effect of FMR1 alleles and genotypes on odds of early
menopause using logistic regression. All women had both FMR1 repeat
alleles in the clinically normal range (<55 copies). All statistical analyses
were performed using Stata 13.1 or 14.1 (StataCorp, College Station,
TX, USA). To avoid assuming that normal length FMR1 alleles would
act by the same dominant genetic mechanism as premutation alleles,
we considered dominant and additive effects by investigating the
effects of each individual FMR1 allele and combinations of alleles
(genotypes).
In each woman, we deﬁned ‘Allele 1’ as the shorter FMR1 repeat allele
and ‘Allele 2’ as the longer of her two alleles. We tested the per repeat
effect of each FMR1 allele as a continuous variable and also classiﬁed each
allele into repeat categories according to size, using previously published
criteria (Gleicher et al., 2014): alleles <26 repeats were considered to be
‘low’, 26–34 repeats to be ‘medium’ and >34 repeats to be ‘high’.
To test the effects of each individual FMR1 allele, statistical analyses
were performed for Allele 1 and Allele 2 separately. Allele length was trea-
ted in three ways: as a continuous variable, as a nominal categorical vari-
able (comparison of low and high to medium length as the reference
category) or as an ordinal categorical variable (analysed as a continuous
variable ordered from low to high).
We also analysed the effect of the FMR1 repeat allele combination,
or genotype. We included each allele as a continuous variable in the
same model, with/without an interaction term (Allele 1 × Allele 2).
We generated six genotype categories from the combinations of
repeat length category for the two alleles: low/low, low/medium,
low/high, medium/medium, medium/high, high/high. The genotypes
were treated as either nominal variables (comparing each genotype to
medium/medium) or as ordinal variables (analysed as a continuous
variable), deﬁning the order in two ways: (i) (a) low/low, (b) low/
medium, (c) low/high, (d) medium/medium, (e) medium/high,
(f) high/high; or (ii) (a) low/low, (b) low/medium, (c) medium/medium,
(d) low/high, (e) medium/high, (f) high/high. Exploratory analyses were
performed of alternative methods of modelling combinations of the
alleles: as a difference between allele length in an individual or as a mean
allele length.
In a secondary analysis, we investigated the relationship between FMR1
alleles and genotypes with age at natural menopause in the 3805 postme-
nopausal women in our study. This was a smaller number than in the case–
control study because not all controls were postmenopausal and so some
were not included. The residuals of the regression on menopause age
were not normally distributed due to overrepresentation of early meno-
pause cases in the analysis; therefore, we applied a statistical correction to
transform the data to a normal distribution. Brieﬂy, this method ranked
the observed values of age at menopause (randomly ordering tied values),
then converted these to a percentile of a standard normal distribution.
Sensitivity analyses were carried out by conditional logistic regression
analyses in 1559 fully matched case–control pairs, and by repeating the
logistic regression analyses restricted to women of white ethnicity and
including smoking status at time of study entry as a covariate. Smoking sta-
tus and ethnicity were available for all women analysed (Table I). In the
analysis of menopause as a quantitative trait, we also tested the models
separately in the control group. Earlier exploratory analysis with meno-
pause before 40 years as the outcome was consistent with the main ana-
lysis (not presented).
Figure 1 Percentage of FMR1 alleles of each length in early menopause cases (n = 4236) and controls (n = 4430).
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Statistical power was estimated using Quanto (http://biostats.usc.
edu/Quanto.html). We estimated the size of genetic effect we could
detect at 80% power for an additive mode of inheritance comparing the
low/low genotype with low/medium and medium/medium. For case–
control models, we assumed a population prevalence of 5% for early
menopause.
Results
Repeat distribution
The length of the FMR1 allele repeat ranged from 7 to 54 copies
(Fig. 1). The distribution of the FMR1 allele was consistent with previ-
ous studies with a mode at 30 copies, and secondary peaks at 20 and
23 copies (Fu et al., 1991; Peprah, 2012), with similar distributions in
the early menopause cases and the rest of the cohort. Almost half of
the women with a natural age at menopause had two medium length
alleles (26–34 repeats), and almost one-third had a combination of
one low allele (< 26 repeats) and one medium allele (26–34 repeats)
(Table II).
Age of menopause
In early menopause cases (n = 2118), the median age at natural meno-
pause was 43 years (range 19–45 years, mean 42.5 years, SD 3.1
years) compared with 52 years in the controls (n = 1687, range 46−62
years, mean 52.1 years, SD 3.1 years), although 24% (n = 528) of con-
trols were premenopausal and therefore could not be included in the
mean (Table I).
.................................. .................................. ...................................
.............................................................................................................................................................................................
Table II Number of women by FMR1 genotype, categorised by allele lengths.
Genotype Early menopause cases Controls Postmenopausal women
included in quantitative
trait analysis
n % n % n %
Low/low 130 5.9 101 4.8 204 5.4
Low/medium 710 32.1 662 31.3 1215 31.9
Low/high 88 4.0 77 3.6 145 3.8
Medium/medium 1027 46.4 1035 48.9 1803 47.4
Medium/high 248 11.2 221 10.4 409 10.7
High/high 12 0.5 22 1.0 29 0.8
Total 2215 100.0 2118 100.0 3805 100.0
Note: Low < 26 repeats; medium 26–34 repeats; high 35–54 repeats.
............................................. ....................................................
.............................................................................................................................................................................................
Table III Relationship of FMR1 allele length with early menopause and age at menopause as a quantitative trait.
Model Variables included Early menopause (n = 2215
cases, n = 2118 controls)
Age at natural menopause (n= 3805)
OR 95% CI P Effecta 95% CI P
Allele 1, continuous Allele 1 (continuous) 1.01 1–1.03 0.077 0.00 −0.01–0 0.280
Allele 1, nominal categorical 1. Low 0.92 0.81–1.04 0.173 0.05 −0.01–0.12 0.125
2. Medium ref. ref.
3. High 1.86 0.92–3.78 0.085 −0.26 −0.63–0.1 0.159
Allele 1, ordinal categorical 1. Low 1.11 0.99–1.25 0.075 −0.06 −0.12–0 0.063
2. Medium
3. High
Allele 2, continuous Allele 2 (continuous) 1.00 0.99–1.01 0.750 0.00 −0.01–0.01 0.672
Allele 2, nominal categorical 1. Low 0.80 0.61–1.04 0.094 0.05 −0.07–0.22 0.302
2. Medium ref. ref.
3. High 0.94 0.8–1.11 0.474 0.01 −0.07–0.11 0.679
Allele 2, ordinal categorical 1. Low 1.03 0.9–1.17 0.712 −0.01 −0.08–0.06 0.800
2. Medium
3. High
aEffect size is in standard deviations of inverse normally transformed age at menopause.
Notes: OR, odds ratio; ref., reference category.
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No association between length of either
FMR1 repeat allele and early menopause
We found no associations for either FMR1 allele with odds of early
menopause (Table III). There was no association between length of
either Allele 1 or Allele 2 of FMR1 and age at menopause as a quantita-
tive trait (P > 0.05 for all) (Table III).
No association between FMR1 repeat
genotype and early menopause
FMR1 repeat genotype was not associated with early menopause or
age at menopause as a quantitative trait (P > 0.05 for all) (Table IV).
Sensitivity analyses
In the fully matched case–control analysis, we found no robust asso-
ciations of either FMR1 allele or genotype with odds of early meno-
pause, although ‘low’ lengths of Allele 2 (OR = 0.72, 95% CI 0.52
−0.99, P = 0.044) and the ‘low/low’ genotype (OR = 0.69; 95% CI
0.50–0.96; P = 0.028) were associated with decreased odds of early
menopause (P > 0.05 for all other results) (Supplementary Table 1
and 2).
We identiﬁed smoking as a potential confounder, since smoking
is associated with earlier menopause (Gold, 2011;Morris et al.,
2012). Consistent with this, there was an association between
being a current smoker and earlier menopause in our analyses
(OR = 2.13; 95% CI 1.65–2.75; P = 6.4 × 10–9); however, length
of FMR1 allele or genotype was not associated with smoking
(P > 0.05 for all) (data available on request). When the analyses
were adjusted for smoking, the results were consistent with the
main analysis (data available on request). The results remained
consistent with the main analysis when analyses were restricted
to women of white ethnicity (data available on request) or when
the secondary analysis of age at menopause was carried out in
only the control group (Supplementary Tables 3 and 4). In
exploratory analyses, neither mean repeat length nor difference in
repeat length was associated with early menopause or age at
menopause (P > 0.05 for all).
.................................... ............................................
.............................................................................................................................................................................................
Table IV Relationship of FMR1 genotype with early menopause and age at menopause as a quantitative trait.
Model Variables included Earlymenopause (n= 2215
cases, n= 2118 controls)
Age at natural menopause
(n = 3805)
OR 95% CI P Effecta 95% CI P
Allele 1, Allele 2, continuous Allele 1 (continuous) 1.01 1–1.03 0.079 0.00 −0.01–0 0.328
Allele 2 (continuous) 1.00 0.98–1.01 0.805 0.00 −0.01–0.01 0.808
Allele 1, Allele 2 and interaction, continuous Allele 1 (continuous) 0.98 0.9–1.06 0.586 0.00 −0.04–0.04 0.934
Allele 2 (continuous) 0.97 0.91–1.04 0.367 0.00 −0.03–0.04 0.836
Allele 1 × Allele 2 (interaction) 1.00 1–1 0.384 0.00 0–0 0.793
Genotype, nominal categorical 1. Low/low 0.77 0.59–1.01 0.063 0.09 −0.05–0.24 0.202
2. Low/medium 0.93 0.81–1.06 0.265 0.06 −0.02–0.13 0.127
3. Low/high 0.87 0.63–1.19 0.384 0.04 −0.13–0.21 0.619
4. Medium/medium ref. ref.
5. Medium/high 0.88 0.72–1.08 0.230 0.05 −0.06–0.16 0.349
6. High/high 1.82 0.9–3.7 0.098 −0.25 −0.61–0.12 0.190
Genotype, ordinal categorical (order 1) 1. Low/low 1.04 0.99–1.09 0.132 −0.02 −0.05–0 0.110
2. Low/medium
3. Low/high
4. Medium/medium
5. Medium/high
6. High/high
Genotype, ordinal categorical (order 2) 1. Low/low 1.03 0.97–1.09 0.399 −0.02 −0.05–0.01 0.309
2. Low/medium
3 .Medium/medium
4. Low/high
5. Medium/high
6. High/high
OR, odds ratio; ref., reference category.
aEffect size is in standard deviations of inverse normally transformed age at menopause.
Notes: The genotypes were treated as either nominal variables (comparing each genotype to medium/medium) or as ordinal variables, deﬁning the order in two ways:
(i) 1. low/low, 2. low/medium, 3. low/high, 4. medium/medium, 5. medium/high, 6. high/high; (ii) 1. low/low, 2. low/medium, 3. medium/medium, 4. low/high, 5. medium/high, 6.
high/high.
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Discussion
We found no robust association between normal length FMR1 alleles
and early menopause. This is unlikely to be due to a lack of power
since we estimated that we were powered to detect an odds ratio
<0.85 or >1.18 per low allele (<26 repeats) in the analysis of all cases
and controls (with similar values for matched analysis). This is similar in
size to estimated odds ratios for early menopause (≤45 years) of
1.13–1.85 per allele for common single-nucleotide polymorphisms
(SNPs) in the same study cohort (Murray et al., 2011). For the analysis
of age at menopause as a quantitative trait, we estimated that we were
powered to detect a change of about 0.5 years per low allele, similar
to the 0.1–0.9 years per allele effect sizes for common SNPs (Day
et al., 2015). Indeed, we were sufﬁciently powered to detect a strong
effect of smoking on reducing age of menopause, which has been pre-
viously observed in this same study cohort (Morris et al., 2012).
As well as demonstrating no association between normal FMR1
allele length and risk of early menopause, our results corroborate a
null association between FMR1 normal length alleles and quantitative
age at menopause from a population-based study not focussed on
early menopause (Voorhuis et al., 2013). Accelerated loss of ovarian
reserve in women with low alleles and better ovarian reserve with high
alleles has been reported in studies including up to 521 women
(Gleicher et al., 2010, 2012a,b, 2014). Our study is not consistent with
these ﬁndings since lower AMH levels, and hence ovarian reserve, pre-
dict earlier menopause (Aydogan and Mirkin, 2015); however,
reduced ovarian reserve does not necessarily result in POI and this
may explain the discrepancy (Gleicher et al., 2015).
Although we were well-powered to detect an association, our calcu-
lations do not take into account factors affecting the accuracy of the
data collected or that would have reduced our power to detect an
association. Long FMR1 alleles are harder to detect; therefore, women
with homozygous alleles may actually be heterozygotes with an
undetected premutation repeat. Of the 4333 women, 21% were
homozygotes, but there was high concordance between duplicated
samples, and the proportion of homozygotes in early menopause
cases and controls was not statistically different. We would expect
such genotyping errors to result in a higher proportion of homozy-
gotes in early menopause cases, since premutation repeats are a
known aetiological risk factor for early menopause (Sherman, 2000).
Another factor that might have contributed to the lack of an
observed association is the potential dilution of risk of early meno-
pause from misidentiﬁcation of early menopause cases. Previous stud-
ies have observed rounding bias towards reporting values ending in 0
or 5 when women are asked to recall their age at menopause (Hahn
et al., 1997); therefore, some women may have rounded down their
menopause age to 45. We estimate, based on the distribution in our
data by reported age in single years, that this may have occurred in 7%
of early menopause cases. Hence, the consequent dilution of risk
would have been minor and does not account for the lack of an
observed association. We controlled for two potential confounders in
our analysis: ethnicity and smoking. Ethnicity is known to affect FMR1
allele length (Peprah, 2012), and we found no association with
smoking.
In summary, in a large population-based study, we found no associ-
ation between normal length FMR1 repeats and risk of the clinically
relevant outcome early menopause, and replicated a null association
with age at menopause as a quantitative trait. The FMR1 CGG repeat
polymorphism in the normal range does not inﬂuence risk of early
menopause and is therefore unlikely to contribute to genetic suscepti-
bility to early menopause.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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